The consensus statement/recommendation on the prevention of respiratory syncytial virus (RSV) infections with the monoclonal antibody Nirsevimab (Beyfortus®) has been published by the Nirsevimab expert working group, including Pédiatrie Suisse/Pädiatrie Schweiz/Pediatria Svizzera, Kinderärzte Schweiz, Pediatric Infectious disease Group of Switzerland (PIGS), Swiss Society of Neonatology, Swiss Society of Pediatric Pneumology, Swiss Society of Pediatric Cardiology, Swiss Society for Gynecology and Obstetrics / gynécologie Suisse, Swiss society of neuropediatrics, Federal Commission for Vaccination Issues (EKIF / CFV), and Federal Office of Public Health (FOPH)
